Acetaminophen Overdose: NAPQI, Glutathione Depletion, and the N-Acetylcysteine Antidote

What It Is and Why It Matters

Acetaminophen (called paracetamol outside North America) is the most widely used analgesic-antipyretic in the world and is remarkably safe at therapeutic doses (up to 4 g/day in healthy adults). The problem is its narrow toxic-to-therapeutic margin and its ubiquity — it is hidden in hundreds of combination cold, flu, and opioid products, so unintentional "therapeutic misadventure" from stacking products is as dangerous as deliberate self-harm.

• Epidemiology: It is the leading cause of acute liver failure (ALF) in the US and UK, responsible for roughly half of all ALF cases and tens of thousands of ED visits annually.
• Toxic threshold: A single acute ingestion of >150 mg/kg (or >7.5-10 g in an adult) risks hepatotoxicity. Higher risk exists in chronic alcohol use, malnutrition, and fasting.

What makes it clinically treacherous is the asymptomatic early window: a patient who feels fine at hour 6 can be in fulminant liver failure by day 3. Recognition and timely antidote are lifesaving.

The Mechanism: NAPQI and Glutathione Depletion

At therapeutic doses, ~90% of acetaminophen is conjugated by the liver via glucuronidation and sulfation into inert, water-soluble metabolites excreted in urine. Only ~5% is oxidized by cytochrome P450 enzymes — chiefly CYP2E1 (with contributions from CYP1A2 and CYP3A4) — into the highly reactive electrophile NAPQI (N-acetyl-p-benzoquinone imine).

• Normal detox: NAPQI is immediately neutralized by hepatic glutathione (GSH), which donates a sulfhydryl (-SH) group to form a harmless mercapturic-acid conjugate.
• Overdose: Glucuronidation and sulfation saturate, shunting more drug through CYP2E1. NAPQI production surges and glutathione stores are depleted (>70% loss).
• Injury: Unquenched NAPQI binds covalently to cysteine residues on hepatocyte proteins (notably mitochondrial proteins), forming NAPQI-protein adducts. This triggers mitochondrial dysfunction, oxidative stress, ATP depletion, and JNK-mediated cell death.

Injury concentrates in zone 3 (centrilobular) hepatocytes, which have the highest CYP2E1 activity and lowest oxygen tension — producing the classic centrilobular necrosis.

Clinical Presentation and the Four Stages

The hallmark of acetaminophen poisoning is a deceptive early quiescence followed by delayed, potentially fatal liver injury. Symptoms evolve through four recognized stages:

• Stage I (0.5-24 h): Often asymptomatic, or nonspecific nausea, vomiting, malaise, pallor, and diaphoresis. Liver enzymes are normal — a normal exam here is falsely reassuring.
• Stage II (24-72 h, "latent"): The patient may feel better even as transaminases climb. Right-upper-quadrant pain, hepatomegaly, and rising INR, bilirubin, and creatinine signal ongoing hepatic and renal injury.
• Stage III (72-96 h): Peak hepatotoxicity — jaundice, coagulopathy, hepatic encephalopathy, hypoglycemia, lactic acidosis, and acute kidney injury. AST/ALT can exceed 10,000 IU/L.
• Stage IV (4 days-2 weeks): Survivors recover completely; the liver can regenerate to normal histology.

Because massive ingestions may cause early anion-gap metabolic acidosis and altered mental status (from very high acetaminophen levels themselves), a critically ill early presenter should still raise suspicion.

Diagnosis: The 4-Hour Level and the Rumack-Matthew Nomogram

The cornerstone of diagnosis in a single acute ingestion at a known time is a serum acetaminophen concentration drawn at 4 hours or later post-ingestion, plotted on the Rumack-Matthew nomogram.

• Treatment line: The US "150 line" starts at 150 mg/L (~1000 µmol/L) at 4 hours and declines with a half-life-based slope; levels on or above it warrant N-acetylcysteine. (After September 2012 the UK adopted a single, more conservative "100 line" at 100 mg/L at 4 hours and dropped the older "200 line" normal-risk line.)
• Timing caveat: A level drawn before 4 hours cannot be interpreted (absorption incomplete). The nomogram is not valid for chronic/staggered ingestions, unknown time, or extended-release products.

Supporting workup: AST/ALT, INR, bilirubin, creatinine, venous/arterial blood gas, lactate, glucose, and a coingestant screen (salicylate, ethanol). Rising INR and creatinine with markedly elevated transaminases define hepatotoxicity. In late or unknown-timing presentations, treat empirically if transaminases are elevated or the level is detectable with liver injury — do not wait for the nomogram.

Management: Why N-Acetylcysteine Works

N-acetylcysteine (NAC) is the antidote and is nearly 100% hepatoprotective when started within 8-10 hours of ingestion. Its mechanisms map directly onto the toxin's pathway:

• Glutathione precursor: NAC is a cysteine donor that replenishes hepatic glutathione, restoring the capacity to neutralize NAPQI.
• Direct NAPQI scavenging: Its sulfhydryl group directly conjugates and detoxifies NAPQI.
• Non-specific benefits: Enhances sulfation, improves microvascular blood flow and oxygen delivery, and acts as a free-radical scavenger — useful even in late/established liver failure.

Also give activated charcoal if the patient presents within ~1-2 hours. NAC is given IV (21-hour or newer 2-bag regimens) or orally; the classic 3-bag IV protocol totals ~300 mg/kg. Even patients presenting late (>24 h) with hepatotoxicity benefit and should receive NAC. For those progressing to fulminant failure, the King's College Criteria guide transplant referral: arterial pH <7.30, or the triad of INR >6.5 (PT >100 s), creatinine >3.4 mg/dL, and grade III/IV encephalopathy. Lactate >3.5 mmol/L is a supportive marker.

Mimics, Pitfalls, and Clinical Significance

Several traps catch clinicians:

• The reassuring well-appearing patient: Normal labs at hours 4-12 do not exclude lethal toxicity. Decisions rest on the drug level and nomogram, not symptoms.
• Staggered/chronic ingestions: The nomogram fails here. Treat based on total dose, transaminase elevation, and a detectable level with liver injury.
• High-risk hosts: Chronic alcohol use, isoniazid, and phenytoin induce CYP2E1, increasing NAPQI; malnutrition and fasting deplete baseline glutathione — both lower the toxic threshold.
• Massive ingestions (>30 g): Can cause early coma and lactic acidosis and may need a modified, higher NAC dose and even hemodialysis.

Distinguish acetaminophen-induced ALF (transaminases often >3500, relatively lower bilirubin) from viral or ischemic hepatitis and from other toxic causes (e.g., Amanita phalloides). The take-home: acetaminophen toxicity is common, initially silent, and one of the few poisonings with a highly effective antidote — outcome hinges entirely on early recognition and timely NAC.

The four clinical stages of acetaminophen toxicity and their timing

Stage	Time after ingestion	Clinical features	Labs
I	0.5-24 h	Asymptomatic or nausea, vomiting, malaise, diaphoresis	Usually normal; AST/ALT normal early
II (latent)	24-72 h	Symptoms improve; RUQ pain, hepatomegaly begin	AST/ALT rising; INR, bilirubin, creatinine climbing
III (hepatic)	72-96 h	Peak hepatotoxicity: jaundice, encephalopathy, coagulopathy, AKI	AST/ALT often >1000 (may exceed 10,000); rising INR, lactate, ammonia
IV (recovery)	4 days-2 weeks	Resolution if survived; complete histologic recovery possible	LFTs normalize over days to weeks